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In recent years, genome-wide association studies have identified 58 independent risk loci for 
coronary artery disease (CAD) on the autosome. However, due to the sex-specific data structure of 
the X chromosome, it has been excluded from most of these analyses. While females have 2 copies 
of chromosome X, males have only one. Also, one of the female X chromosomes may be inactivated. 
Therefore, special test statistics and quality control procedures are required. Thus, little is known 
about the role of X-chromosomal variants in CAD. To fill this gap, we conducted a comprehensive 
X-chromosome-wide meta-analysis including more than 43,000 CAD cases and 58,000 controls from 
35 international study cohorts. For quality control, sex-specific filters were used to adequately take 
the special structure of X-chromosomal data into account. For single study analyses, several logistic 
regression models were calculated allowing for inactivation of one female X-chromosome, adjusting 
for sex and investigating interactions between sex and genetic variants. Then, meta-analyses including 
all 35 studies were conducted using random effects models. None of the investigated models revealed 
genome-wide significant associations for any variant. Although we analyzed the largest-to-date 
sample, currently available methods were not able to detect any associations of X-chromosomal 
variants with CAD.
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In the last years, genome-wide association studies (GWAS) have uncovered numerous chromosomal risk loci 
for various complex diseases. Specifically, for coronary artery disease (CAD), 58 independent risk loci have been 
identified and verified in independent replication datasets1. However, a large part of the estimated heritability of 
CAD is not yet explained. This could be due partly to the fact that the X chromosome has routinely been excluded 
from GWAS. One reason for this is that the data has a different, sex-specific structure and, therefore, requires 
special analytical tools including special quality control and test statistics2. Thus, despite the profound effects of 
gender on the manifestation of CAD, no systematic association analyses of X-chromosomal variants with CAD 
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have been reported so far. Therefore, an analysis of the X-chromosome from GWAS data might help to narrow the 
gap of missing heritability and help to yield new insights into the genetics of CAD.
X-chromosomal variants might be expected to play a role in the pathophysiology, since sex-specific features 
are known for CAD. Specifically, the risk to develop CAD varies between males and females independent from 
other risk factors. The symptoms of myocardial infarction (MI) as well as the prognosis after MI differ between 
males and females. Males are more likely than females to manifest CAD at young age, but females are more likely 
than males to die of a first MI. Furthermore, heart disease is the most common cause of death for females3. Thus, 
the analysis of X-chromosomal variants could help to explain the sex differences in CAD.
To comprehensively investigate the association of variants on chromosome X and CAD, we collected data 
from 35 world-wide study cohorts. All participating studies were part of the CARDIoGRAM + C4D consor-
tium1. At each study site, quality control on subject level was performed, data were imputed on the basis of the 
1000 genomes reference panel, and X chromosome-adapted association tests were calculated. After this, data 
were analyzed centrally at the University of Lübeck, where further quality control and the meta-analysis of all 35 
studies were conducted. In the following, we will present the results of the association analysis of about 200,000 
X-chromosomal single nucleotide polymorphisms (SNPs) with CAD on a sample of more than 100,000 subjects 
including more than 43,000 cases and 58,000 controls.
Results
Details on the investigated studies are summarized in Table 1. For each of the 35 studies, logistic regression 
models with additive scoring for the SNP were used. To account for the sex-specific structure of X-chromosomal 
Study Ancestry Cases (% females) Controls (% females) % MI* (in cases)
ADVANCE White European 275 (59.9) 311 (60.7) 100.0
BioMe_AfrAm African American 362 (66.5) 2778 (70.9) 36.0
BioMe_EurAm European American 487 (35.0) 1382 (61.6) 30.4
BioMe_HisAm Hispanic American 758 (55.1) 3338 (71.3) 36.7
Cardiogenics White European 391 (13.7) 410 (60.8) 12.5
CATHGEN White European 1191 (31.4) 646 (58.9) 48.1
CCGB_2 White European 1547 (21.8) 344 (45.0) 60.3
EGCUT White European 658 (49.6) 5841 (56.1) 19.6
FGENTCARD Libanese 1802 (25.0) 466 (50.8) 16.0
FINCAVAS Finnish European 774 (21.2) 647 (44.8) 12.4
FINRISK/PredictCVD Finnish European 677 (30.9) 1200 (42.7) 40.0
GerMIFSI White European 637 (33.9) 1644 (51.2) 100.0
GerMIFSII White European 1222 (21.0) 1298 (48.5) 100.0
GerMIFSIII White European 1096 (20.5) 1509 (52.2) 100.0
GerMIFSIV White European 1002 (36.0) 1147 (61.9) 100.0
GerMIFSV White European 2459 (24.5) 1611 (53.0) 100.0
HPS White European 2700 (23.9) 2748 (72.5) 65.0
HSDS White European 206 (0.0) 258 (0.0) 45.6
ITH White European 402 (29.4) 449 (32.9) 100.0
LIFE-Heart White European 1531 (24.8) 768 (50.3) 44.0
LOLIPOP Indian Asian 2791 (18.5) 3757 (14.1) 43.9
LURIC White European 2347 (25.5) 621 (48.0) 62.9
MEDSTAR White European 875 (34.4) 447 (55.9) 100.0
MIGEN White European 2905 (24.8) 2998 (26.9) 100.0
OHGS_A2 White European 921 (24.9) 1001 (50.5) 64.3
OHGS_B2 White European 1183 (22.4) 1391 (49.5) 55.6
OHGS_C2 White European 833 (6.4) 317 (66.7) 44.3
PENNCATH White European 933 (29.2) 468 (58.8) 100.0
PIVUS White European 119 (24.3) 830 (54.7) 77.3
PROCARDIS White European 5719 (29.2) 6526 (62.5) 80.0
SDS Indian Asian 176 (29.5) 1421 (49.0) 100.0
THISEAS White European 423 (21.3) 593 (56.3) 60.1
TWINGENE White European 814 (29.1) 5999 (55.8) 70.5
ULSAM White European 322 (0.0) 857 (0.0) 84.2
WTCCC White European 1922 (20.9) 2930 (51.2) 71.5
Total — 43120 (28.2) 58291 (50.0) 66.7
Table 1.  Cohort descriptives of the 35 studies participating in the 1000G coronary artery disease meta-
analysis of the X-chromosome. *MI = myocardial infarction.
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data, sex was always included as a covariate. In addition, interactions between SNP and sex were investigated. 
Where appropriate, further covariates could be included. Since one of the two female X-chromosomes may or 
may not be inactivated at a specific locus, models were calculated that assumed inactivation as well as not assum-
ing inactivation.
The study-wise numbers of SNPs excluded due to quality control are given in Supplementary Tables S1 and S2. 
The inspection of inflation factors4 and Q-Q-plots (see also Supplementary Fig. S1) did not reveal any systematic 
inflation of specific studies. Thus, all studies were included in the meta-analysis.
None of the statistical models used for the meta-analysis revealed a genome-wide significant association 
with CAD for any SNP. Association results for the model without inactivation assumption and without SNP*sex 
interaction are presented in Fig. 1. Results of the other models are comparable and presented in Supplementary 
Figs S2–S6.
Subgroup and sensitivity analyses. To investigate possible sex-specific effects, we conducted subgroup 
analyses of males and females separately. Association plots of these models are presented in Supplementary 
Figs S7 and S8. Again, no genome-wide significant associations were to be observed. To exclude a possible bias 
introduced by including study cohorts of non-European ancestry, we performed a subgroup analysis including 
only the 31 studies with European background. Excluding non-European studies did not show additional associ-
ations either (Supplementary Figs S9–S14). Finally, to eliminate possible influences of the quality control param-
eters, we varied our criteria on missing frequencies and imputation quality. Performing stricter quality control 
reduced the number of SNPs available for meta-analysis to about 90,000 (depending on model, between 90,658 
and 96,502). Results of these analyses were comparable to the results from the primary analyses. Thus, none of the 
sensitivity analyses did reveal novel associations, supporting the null findings of the main analyses.
Power. We estimated the power of our study overall as well as in the smallest subgroup analyzed, i.e. the sub-
group of females, as functions of the odds ratio and the effect allele frequency (EAF) (Fig. 2). In the entire sample 
of males and females, odds ratios of 1.1 or 1.11 would have reliably been detected with an EAF of 0.1 or higher. 
Even in the female subgroup, odds ratios of 1.15 and higher would have been detectable with a sufficiently large 
probability.
Discussion
Although the presented meta-analyses included more than 100,000 subjects (the largest to date), with 43,120 
CAD cases (28.2% women) and 58,291 controls (50% women), no genome-wide significant associations could 
be detected. This negative finding was independent of the model chosen for analysis. There were no sex-specific 
associations for CAD. Stricter quality control or excluding non-European studies did not reveal any different 
findings.
The NHGRI GWAS catalog5,6 reports 52 genome-wide significant associations of variants on chromosome 
X with more than 600 traits. All of the reported studies are of much smaller sample size (less than 50,000 sam-
ples) and used fewer methods than our analyses. Yet, they successfully discovered associations. However, no 
genome-wide significant associations with CAD or any other correlated phenotype have been reported on the 
X chromosome. The only gene reported for CAD on chromosome X is CHRDL1 with a p-value of 9 · 10−7 for 
rs59430577, but this did not replicate in our analyses (p = 0.0172 for the model without inactivation assumption 
and without SNP*sex interaction). As our power estimates indicated (Fig. 2), in such a large dataset, the statistical 
power to detect medium to large effects is high, and only small effects are likely to have been missed. Therefore, 
the most natural explanation to the negative finding of this meta-analysis is that there are no substantial associa-
tions of X-chromosomal variants with CAD.
However, since the progression and the symptoms of CAD, as well as the prognosis after MI, are sex-specific, 
it may be that the genetics of chromosome X are more complex than previously assumed. For example, the 
inactivation patterns are not yet understood completely, and it has been shown that inactivation of the female 
X-chromosome can be cell-specific. The silenced X-chromosome is not necessarily chosen randomly, and 
silenced regions can differ between females8,9. Although we evaluated models with and without the assumption 
of inactivation, different inactivation patterns between females at one locus were not taken into account. Nor was 
Figure 1. Chromosome-wide association results. The statistical model assumes no inactivation and no 
SNP*sex interaction. Shown are logarithmized random effects p-values of all 184,673 quality controlled SNPs in 
order of physical position in mega base pairs (mbp).
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non-random inactivation incorporated into the model. This could affect the power of the test statistics that were 
used and might result in an analysis that is less powerful than estimated. Further, it might be argued that the use of 
other statistical methods could have yielded significant findings. Specifically, most other studies (e.g. refs 10 and 
11) are based on a separate analysis of males and females with a subsequent summary by a classical or sex-specific12 
meta-analytic method. In contrast, we followed the approach to directly compute joint test statistics for males and 
females, taking the different structure of chromosome X in the sexes into account. However, examples for both 
methodological approaches have been compared in simulations13,14 with the overall result that the joint tests have 
greater power unless there are relevant differences in the effect sizes between males and females, which is not to 
be expected given our sex-specific subgroup analyses. Another potential limitation could be the lower coverage 
of chromosome X than autosomal chromosomes2,15. Specifically, depending on the specific genotyping chip, the 
distance between two known variations16 averages roughly 700 to 10,000 bp on all chromosomes but about 1400 
to 22,500 bp on chromosome X. Accordingly, the median distance in our studies is 11,300 bp, so that the coverage 
is less than optimal but comparable to the use of an older genotyping array in general. More generally, the use of 
these technologies is restricted to finding associations with SNPs only; the effect of other structural variants or even 
having XX instead of XY cannot thus be detected. Another explanation for the lack of significant associations could 
be problems with the imputation. Using the IMPUTE2 algorithm, as most of the study sites did, a mixture of two 
populations, males and females, is imputed together. Perhaps this leads to a bias that has not been taken adequately 
into account. From a clinical perspective, coronary disease and its manifestations differ in women, including a 
larger proportion of younger women with myocardial infarction having the distinct pathophysiology of coronary 
dissection, which could complicate the dissection of genetic influence according to sex.
Although we have analyzed the largest sample to date, we were not able to detect genome-wide significant 
associations between chromosome X variants and CAD with currently available methods. Due to this lack of 
significant associations, the sex-specific differences in CAD are still unexplained. The genetics of chromosome X 
may be more complex than has been assumed, so that more sophisticated test statistics which allow for these com-
plex biological processes would be required to detect associations of variants on the X-chromosome with CAD.
Materials and Methods
Sex-specific structure of chromosome X. One reason why chromosome X is usually excluded from 
GWAS is that the data has a different, sex-specific structure and, therefore, requires special analytical tools15,17. 
While there are two copies of each autosomal chromosome, males carry only one copy of the X chromosome 
whereas females, again, carry two copies. Therefore, at each SNP, females can carry one of three possible gen-
otypes; that is, they can have 0, 1 or 2 copies of a specific allele. In contrast to this, there are only two possible 
genotypes for males, corresponding to 0 or 1 copies of a specific allele. Only for the so-called pseudo-autosomal 
Figure 2. Estimated power. The power to detect an effect was estimated in dependence of the odds ratio (OR) 
and the effect allele frequency (EAF) using software Quanto (version 1.2.4 from May 2009). Parameters used for 
simulation: Binary (disease) phenotype, significance level α = 5·10−8, disease prevalence kP = 0.1, log-additive 
genetic model, no gene-environment interaction. (A) Effective Ncases = 27,640, 1.5817 effective controls per 
effective case (corresponding to 43,718 effective controls), (B) Female Ncases = 12,160, 2.3968 female controls per 
female case (corresponding to 29,145 female controls).
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regions, there exist homologous loci on the Y chromosome, and males can have up to 2 copies of a specific allele. 
In addition, one of the two female X chromosomes might be inactivated. In each cell, one of the two female 
X chromosomes is randomly selected to be silenced18. This means that the expression levels of this chromosome 
are much lower than for the second chromosome in the cell. This mechanism of dose compensation should 
result in comparable expression levels for males and females despite the different number of chromosome copies. 
However, this inactivation is incomplete: while some genes or regions will be completely inactivated, some genes 
might show expression levels that are reduced only slightly or not at all8. Therefore, to analyze X-chromosomal 
data, special quality control and test statistics are required2. Most of the quality control needs to be done sepa-
rately for males and females, and test statistics for chromosome X should take into account the different data 
structure for males and females, for example by including sex as a covariate into the model. The choice of the best 
statistical test depends on the underlying genetic model and the inactivation patterns at a specific locus13.
Study cohorts. The meta-analysis includes data from 43,120 cases with CAD and 58,291 controls from 35 
studies with 28.2% female cases and 50.0% female controls (for details, see Table 1). A subject was regarded as a 
CAD case if he/she had an inclusive CAD diagnosis, e.g. MI, acute coronary syndrome, chronic stable angina, or 
coronary stenosis > 50%. More detailed information on the study cohorts can be found in the meta-analysis of 
autosomal variants of the CARDIoGRAMplusC4D Consortium1 which included most of the samples presented 
here. Thirty-one of the 35 studies consist of subjects with European ancestry, two study cohorts are of Asian 
ancestry, one of Hispanic and one of African ancestry.
Genotyping and imputation to 1000G data. Details on the genotyping arrays used for each study 
cohort have been published before1. At each study site, untyped SNPs were imputed on the basis of the 1000 
genomes phase 1 version 3 reference panel19. Although this reference panel includes insertion and deletion vari-
ants (indels), these were excluded from further analyses. Prior to any quality control, there were 1,193,934 SNPs 
available for the non-pseudo-autosomal region of chromosome X.
Quality control. Quality control at subject level and at variant level was performed at each study site prior 
to imputation and association analysis as described previously1. In addition to quality criteria typically used for 
analyses of autosomal SNPs20,21, all subjects for whom the genotypic and reported sex could not be assigned 
unambiguously were excluded. Post-imputation quality control at SNP level was done centrally and in the same 
manner for all contributing studies. Here, SNPs were excluded if one of the following criteria was fulfilled: 
(1) ≥ 25% missing genotypes in either female or male cases or controls, (2) deviation from Hardy-Weinberg 
equilibrium in female controls with p < 0.0001, (3) minor allele frequency < 1% in either males or females, and 
(4) imputation quality score (INFO for IMPUTE222–25 and r2 for Minimac22,26) < 0.5. For sensitivity analysis, we 
additionally applied stricter criteria for imputation quality (INFO > 0.7) and missing genotypes (< 2% in either 
female or male cases or controls).
Study-wise association analysis. Study-wise association analyses were calculated at each study 
site. Logistic regression models with additive scoring for the SNP were used. The sex-specific structure of 
X-chromosomal data implies different variances in male and female sub-samples. To account for this, sex needs 
to be included as a covariate in the model. In addition, interactions between SNP and sex were investigated. 
Where appropriate, additional covariates to adjust for population stratification have been included in the model, 
for example in the form of variables calculated from a principal component analysis or variables describing the 
ethnic background of the subjects.
Since one of the two female X-chromosomes may or may not be inactivated at a specific locus, models were 
calculated that assumed inactivation as well as not assuming inactivation. If inactivation is present at a locus, 
two risk alleles of a female subject should show similar expression levels as compared to one risk allele in a male 
individual. Therefore, while the female genotypes for such a SNP are coded 0, 1 or 2, according to 0, 1 or 2 alleles, 
the genotypes for males should be coded 0 or 2 according to 0 or 1 alleles. If no inactivation occurs, the expression 
levels of one allele in females should be the same as one allele in males. Therefore, while the coding of female 
genotypes is unchanged, male genotypes should now be coded 0 or 1, according to 0 or 1 alleles. As an alternative 
to assuming complete or no inactivation approach, Wang et al.27 proposed likelihood ratio tests for the situation 
of non-random or skewed inactivation, which can be more powerful in the case of non-random inactivation. 
However, given that the gain in power is small and that these tests are available in Matlab28 only, which was not 
available for many of the participating study sites, we refrained from using this particular approach. These con-
siderations resulted in four models being investigated (Table 2).
Post-hoc quality control. After calculation of the association analyses for each single study, post-hoc qual-
ity control was applied for all studies. To control for population stratification or other sources of inflation of 
p-values, inflation factors according to Devlin and Roeder4 were calculated, and plots of expected versus observed 
test statistics were inspected visually. In addition, for each SNP, mean EAFs over all studies were calculated and 
compared to the study-wise EAFs. SNPs with extreme deviations (> 0.1, corresponding to more than 4 standard 
deviations) from the mean EAF were excluded from further analyses. Finally, only SNPs for which at least half of 
the studies were available were included in the meta-analyses.
Meta-analyses. For the meta-analyses of the 35 studies, random effect models were calculated for each of the 
four models defined in Table 2. In the same way, meta-analyses of the effect estimates for the SNP*sex interaction 
were performed. In all of these analyses, outlier analyses according to Preuß et al.20 were performed to exclude 
studies with extremely inflated effect estimates.
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Sensitivity and subgroup analyses. We conducted the following sensitivity and subgroup analyses: 
(1) Subgroup analyses of males and females separately with subsequent meta-analyses to gain further insight 
into sex-specific effects; (2) Subgroup meta-analysis including only the 31 studies with European background; 
(3) Meta-analysis of SNPs fulfilling stricter quality criteria as described above.
Power estimation. Using the software Quanto, version 1.2.429, we estimated the power of our analyses in two 
ways. Firstly, to take into account our entire sample of males and females, a simple combination of the data is not 
possible due to the sex-specific structure of X chromosomal variants. We therefore followed Clayton30 in assuming 
that the variance in males has twice the size of that in females in the additive model assuming inactivation. Therefore, 
we assumed that the effective sample size in males is halved, and this was added to the female sample size. Power was 
then estimated as a function of the odds ratio and the EAF at a significance level of α = 5·10−8, a disease prevalence 
kP = 0.1, and a log-additive genetic model. Secondly, we estimated the power for the smallest subgroup analyzed, i.e. 
the subgroup of females. The parameters in Quanto were set to the same values as before.
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Model Mathematical descriptiona SNP*sex interaction Coding of SNP Inactivation
I Logit(CAD) = β0 + β1 · SNP + β2 · sex No Females: 0, 1, or 2; Males: 0 or 1 No
II Logit(CAD) = β0 + β1 · SNP + β2 · sex No Females: 0, 1, or 2; Males: 0 or 2 Yes
III Logit(CAD) = β0 + β1 · SNP + β2 · sex + β3 · SNP*sex Yes Females: 0, 1, or 2; Males: 0 or 1 No
IV Logit(CAD) = β0 + β1 · SNP + β2 · sex + β3 · SNP*sex Yes Females: 0, 1, or 2; Males: 0 or 2 Yes
Table 2.  Association models for chromosome X. aFor each study, further covariates to adjust for population 
stratification have been added to the model where appropriate.
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